BiotechTube
Hemorai

Hemorai

San Francisco, United States· Est.
hemorai.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2018 and headquartered in San Francisco, Hemorai is a private, pre-revenue company focused on AI-powered diagnostic software for hematology. Its core platform uses machine learning algorithms to analyze peripheral blood smear images, potentially improving the speed, accuracy, and consistency of diagnosing blood disorders like anemias, leukemias, and infections. The company targets the clinical laboratory and digital pathology markets, aiming to integrate its software as an aid within existing diagnostic workflows.

Hematology

Technology Platform

AI/ML software for automated analysis, classification, and quantification of blood cells and morphological abnormalities from digital blood smear images.

Opportunities

The global shift towards digital pathology and automation in clinical labs creates a strong tailwind for AI diagnostic aids.
Labor shortages and the need for standardized, quantitative analysis in hematology present a clear market need.
The technology platform could be expanded beyond primary diagnosis to areas like clinical trial support and specialized cell detection.

Risk Factors

Regulatory hurdles for AI-based software as a medical device are significant and evolving.
Competition is intense from both established hematology instrument companies integrating AI and other AI pathology startups.
Market adoption requires proving cost-effectiveness and seamless integration into existing laboratory workflows against entrenched practices.

Competitive Landscape

Hemorai competes with large diagnostics companies (e.g., Sysmex with its DI-60/DI-H series, Beckman Coulter) that offer integrated digital morphology solutions. It also faces competition from broader AI pathology platforms (e.g., Paige, PathAI) expanding into hematology, and other specialized startups focusing on blood smear analysis. Differentiation requires superior accuracy, workflow integration, and a clear value proposition.

More companies in Digital Health & Biotech SaaS →More companies in United States →